Home > Dermatology > EADV 2022 > Deucravacitinib demonstrates stable, long-term maintenance

Deucravacitinib demonstrates stable, long-term maintenance

Presented By
Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA
EADV 2022
Phase 3, POETYK-PSO-1
The newly, FDA-approved weapon in the armamentarium of psoriasis treatments, deucravacitinib, performed with durable efficacy. Up to week 112, the results in various outcome measures were consistent with those at week 52. In the pivotal POETYK-PSO-1 trial (NCT03624127), patients were treated in a placebo-controlled fashion from day 1 to week 16, after which placebo patients were able to cross over to active deucravacitinib, given at a dose of 6 mg once daily (approved dose). At the pivotal primary endpoint, 58.4% of the patients treated with deucravacitinib achieved PASI75 compared with 12.7% of the placebo-treated patients. This rate further rose to 69.3% at week 24 and 65.1% after 1 year. At the same time points, the results for the static Physician's Global Assessment (sPGA) of 0/1 were within a similar range: 53.6%, 58.7%, and 52.7%, respectively. At EAD...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on